N-Acetylgalactosamine (GalNAc), is an amino sugar derivative of galactose. In humans it is the terminal carbohydrate forming the antigen of blood group A. [1] It is typically the first …

GalNAc-siRNA conjugates are a simple solution to the siRNA delivery problem for liver hepatocytes and have shown the RNAi (and antisense oligonucleotide) field the path forward …

Oct 14, 2021 · We will elaborate on the properties and functions of the ASGPR and review the evolution of GalNAc technology and their application in the delivery of oligonucleotide …

Aug 5, 2020 · Targeted delivery of oligonucleotides to liver hepatocytes using N-acetylgalactosamine (GalNAc) conjugates that bind to the asialoglycoprotein receptor has …

Unlike complicated LNP formulations, GalNAc-siRNA conjugates are a simpler, smaller, and compositionally defined approach for hepatic delivery. A complete GalNAc-siRNA can be …

Aug 5, 2020 · Targeted delivery of oligonucleotides to liver hepatocytes using N-acetylgalactosamine (GalNAc) conjugates that bind to the asialoglycoprotein receptor has …

GalNAc conjugates – GalNAc, or N-acetylgalactosamine, is a sugar molecule that can recognize and bind to a cell surface protein, the asialoglycoprotein receptor (ASGPR), which is …

N-acetylgalactosamine (GalNAc) is a well-defined liver-targeted moiety benefiting from its high affinity with asialoglycoprotein receptor (ASGPR).

We hypothesized that peptides with reduced main-chain flexibility and strategically positioned N -acetylgalactosamine (GalNAc) moieties could enhance liver selectivity and uptake efficiency.

Short-interfering RNA (siRNA)-induced RNA interference (RNAi) responses have great potential to treat a wide variety of human diseases. A number of N -acetylgalactosamine (GalNAc) …